key: cord-0827653-dnlh4w7d
authors: Prakash Yadava, Om
title: Lung transplant for COVID-19—a bone of contention!
date: 2022-05-21
journal: Indian J Thorac Cardiovasc Surg
DOI: 10.1007/s12055-022-01372-9
sha: 82efef7a68fa5f53cef39fe7196433b84f625f70
doc_id: 827653
cord_uid: dnlh4w7d

nan

LT in COVID-19 patients. A countervailing retort from the advocates-whatever little evidence we have of mid-term one-year survival of LT for COVID-19, it is very satisfactory at 94% in a series of 60 patients [6] , which is not much different from non-COVID indications for LT. However, according to the data presented at the recent Annual Meeting of the American College of Chest Physicians (CHEST 2021), mortality rate in ECMO patients during the 2 nd wave of the COVID-19 pandemic (Nov 2020-Mar 2021) was 69%, with sepsis occurring as a consequence of increased use of immuno-modulation therapy, as the commonest (32%) cause.

In their riposte to the former observation regarding the wait-list queue, the authors have even gone on to say that despite COVID-19 patients jumping the wait-list, the patients which were displaced did not suffer and there was no increase in the wait-list mortality [6] . Lepper et al.'s [5] proposal to allot the lung allocation score to zero for COVID-19 patients with ARDS does not find favour with Bharat et al.-'Denying a life-saving treatment to this population would be a disservice and, in our view, unethical' [6] . In fact, they suggest that the increased need for donor organs can be met through use of extended criteria donor lungs, hepatitis C donors, and ex vivo lung perfusion techniques [6] . However, this is just one report and the jury is still out.

Another contentious issue is the time period at which lung parenchyma should be deemed 'unrecoverable' [7] . In Bharat et al. series [3] , LT was carried out at a median of 69 days (IQR (interquartile range) 51-82) after COVID-19 onset and 49 days (IQR 38-80) of ECMO support, at which time period they deemed lung injury irreversible. To the contrary, Schmidt et al. [8] from France reported 50% salvage, sans LT, in 12 patients on prolonged (> 50 days) ECMO support for COVID-19, thereby challenging the early cut-off presumed by Bharat et al. [3] . Anecdotal successful LT after 6 months of extended ECMO support for COVID-19-induced ARDS has been reported, though the patient died at 9 months due to consequences of acute rejection [9] . Whether delayed LT, after prolonged ECMO support, will compromise outcomes remains an unexplored issue. No matter the debate, LT is an important tool in the salvage armamentarium of a physician against COVID-associated ARDS. Its applicability obviously will vary according to the cultural and philosophical beliefs of the patients, society, and the medical profession. Availability of resourceshuman, infrastructural, and fiscal-besides support of the regulatory bodies, the government, and other non-governmental bodies would be integral to its success. Multidisciplinary peer support, both overt and covert abetment and encouragement of the institution, and the benefaction of its administrative hierarchy, are pre-requisites for the success of such resource-intensive endeavours, trying to change the paradigm of treatment of end-stage pulmonary dysfunction and drive the goal posts into 'Devil's (hic ….death's) own territory.

Bravo you Transplant folks. This issue is dedicated to you all.

Funding None.

Informed consent Not required.

Conflict of interest Nil.

A pandemic of acute respiratory distress syndrome -role of lung transplant in coronavirus disease-2019 -Associated respiratory failure

Lung transplant -shifting sands ! Indian

Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries

Lung transplantation for acute respiratory distress syndrome: A multicenter experience

Lung transplantation for COVID-19-associated ARDS

Lung transplantation for COVID-19-associated ARDS -Authors' reply

Lung transplantation for COVID-19-associated ARDS

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Lung transplant after 6 months on ECMO support for SARS-CoV-2-induced ARDS complicated by severe antibody-mediated rejection